| http://www.w3.org/ns/prov#value | - ???Patent expiry is one of the key challenges for the growth of this market and has resulted in a slowdown in recent few years due to patent expiries of blockbusters such as Evista, the Premarin family, Actonel, and other drugs,??? says BCC Research biotechnology analyst Dr. Ritu Thakur Dangi. ???However, the launch of novel therapies (e.g., elagolix, odanacatib, Femitra, among others) in the late
|
